Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 512-517

  Neil, H A W ^a,b   Ceglarek, U ^c   Thiery, J ^c   Paul, S ^b,d   Farmer, A ^a,b   Holman, R R ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cholesterol synthesis; N 3 polyunsaturated fatty acids; Phytosterols; Plant sterols; Randomised controlled trial; Statins; Sterol absorption; Type 2 diabetes

Indexed keywords

ATORVASTATIN; BRASSICASTEROL; CAMPESTEROL; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LANOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; SITOSTEROL; STIGMASTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; HEPTANOIC ACIDS; HUMANS; LANOSTEROL; PHYTOSTEROLS; PYRROLES; TRIGLYCERIDES;

EID: 78649743151     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.09.013     Document Type: Article

References (31)

1. Lu K., Lee M.-H., Hazard S., et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001, 69:278-290.
2. Chan Y.-M., Varady K.A., Lin Y., Trautwein E., et al. Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease. Nutr Rev 2006, 64:385-402.
3. Wilund K.R., Yu L., Xu F., Vega G., et al. Plant sterol levels are not associated with atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol 2004, 24:2326-2332.
4. Sudhop T., Gottwald B.M., von Bergmann K. Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism 2002, 51:1519-1521.
5. Glueck C.J., Speirs J., Tracy T., et al. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism 1991, 40:842-848.
6. Assmann G., Cullen P., Erbey J., et al. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis 2006, 16:13-21.
7. Teupser D., Barber R., Ceglarek U., et al. Genetic regularion of serum phytosterol levels and risk of coronary artery disease. Circ Cardiovasc Genet 2010, 10.1161/circgenetics.109.907873.
8. Lally S.E., Owens D., Tomkin G.H. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Diabetologia 2007, 50:217-219.
9. Stamler J., Vaccaro O., Neaton J., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434-444.
10. Simonen P.P., Gylling H.K., Miettinen T.A. Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 2002, 25:1511-1515.
11. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised controlled trials: a meta-analysis. Lancet 2008, 371:117-125.
12. Holman R.R., Farmer A.F., Hartweg J., et al. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes: the AFORRD trial. Diabetologia 2009, 52:50-59.
13. Erkkila A.T., Lichtenstein A.H., Mozaffarian D., Herrington D.M. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 2004, 80:626-632.
14. Hu F.B., Cho E., Rexrode K.M., Albert C.M., Manson J.E. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003, 107:1852-1857.
15. Hartweg J., Farmer A.J., Holman R.R., Neil H.A.W. Meta-analysis of the effects of n-3-polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 2007, 50:250-258.
16. Hartweg J., Farmer A.J., Perera R., Holman R.R., Neil H.A.W. Meta-analysis of the effects of omega-3-polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in type 2 diabetes. Diabetologia 2007, 50:1593-1602.
17. Lembcke J., Ceglarek U., Fiedler G.M., et al. Rapid quantification of free and esterified phytosterols in human serum using APPI-LC-MS/MS. J Lipid Res 2005, 46:21-26.
18. Tilvis R.S., Miettinen T.A. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 1986, 43:92-97.
19. Bosner M.S., Lange L.G., Stenson W.F., Ostlund R.E. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 1999, 40:302-308.
20. Song B.-L., Javitt N.B., DeBose-Boyd R.A. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metab 2005, 1:179-189.
21. Van Himbergen T.M., Matthan N.R., Resteghini N.A., et al. Comparison of the effects of maximal dose atorvastatin and rosuvastin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009, 50:730-739.
22. Miettinen T.A., Gylling H., Lindbohm N., et al. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141:131-137.
23. Pinedo S., Vissers M.N., von Bergmann K., et al. Plasma levels of plant sterols and the risk of future coronary artery disease in apparently healthy men and women: the prospective Epic-Norfolk population study. J Lipid Res 2007, 48:139-144.
24. Assman G., Kannenberg F., Ramey D.R., et al. Effects of ezetimibe, simvastatin, and ezetimibe-therapy on non-cholesterol sterols in patients with primary hypercholesterolaemia. Curr Med Res Opin 2008, 24:249-259.
25. Silbernagel G., Fauler G., Renner W., et al. The relationship of cholesterol metabolism and plasma plant sterols with severity of coronary artery disease. J Lipid Res 2009, 50:334-341.
26. Finnish 4S Investigators Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. BMJ 1998, 316:1127-1130.
27. Lakoski S.G., Xu F., Vega G.L., Grundy S.M., et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrin Metab 2010, 95:800-809.
28. Jakulj L., Vissers M.N., Groen A.K., et al. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post hoc analysis of the ENHANCE trial. J Lipid Res 2010, 51:755-762.
29. Neil H.A.W., Meijer G.W., Roe L.S. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis 2001, 156(2):329-337.
30. The ASCEND Trial (abstract). Oxford Clinical Trial Service Unit. http://www.ctsuox.ac.uk./ascend/.
31. The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) (abstract). Clinicaltrials.gov identifier: nct00069784. http://www.clinicaltrials.gov/ct/show/nct00069784.